International Name (Active Ingredient): Levofloxacin
Clinical-Pharmacological Group: Antibacterial Agents → Fluoroquinolones
Manufacturer: Ilko Ilac San. Ve Tic. A.S.
Country of Manufacture: Turkey
Dosage Form: 500mg Film-coated tablet N7
Dispensing Regimen: Group II (issued with a prescription in form N3)
Pharmacological properties:
Ilflox is a broad-spectrum antimicrobial agent from the fluoroquinolone group and is the left-handed isomer of ofloxacin. It disrupts the bacterial DNA synthesis process by inhibiting DNA gyrase and IV topoisomerase.
Levofloxacin is active against most strains of microorganisms both in vitro and in vivo:
- Aerobic Gram-positive microorganisms: Corynebacterium diphtheriae, Enterococcus spp. (including Enterococcus faecalis), Listeria monocytogenes, Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus spp. groups C and G (including Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans);
- Aerobic Gram-negative microorganisms: Acinetobacter baumannii, Acinetobacter spp., Actinobacillus actinimycetemcomitans, Citrobacter freundii, Eikenella corrodens, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter spp. (including Enterobacter cloacae), Escherichia coli, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parainfluenzae, Helicobacter pylori, Klebsiella spp. (including Klebsiella oxytoca, Klebsiella pneumoniae), Moraxella cattaralis, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella spp. (including Pasteurella conis, Pasteurella dagmatis, Pasteurella multocida), Proteus mirabilis, Proteus vulgaris, Providencia spp. (including Providencia rettgeri, Providencia stuartii), Pseudomonas spp. (including Pseudomonas aeruginosa), Salmonella spp., Serratia spp. (including Serratia marcescens);
- Anaerobic microorganisms: Bacteroides fragilis, Bifidobacterium spp., Clostridium perfringens, Fusobacterium spp., Peptostreptococcus spp., Propionibacterium spp., *Veillonella spp.;
- Other microorganisms: Bartonella spp., Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Legionella pneumophila, Legionella spp., Mycobacterium spp. (including Mycobacterium leprae, Mycobacterium tuberculosis), Mycoplasma hominis, Mycoplasma pneumoniae, Rickettsia spp., Ureaplasma urealyticum.
Indications and Dosage:
- Acute Sinusitis: 500 mg once daily. Treatment course: 10-14 days.
- Chronic Bronchitis Exacerbation: 250-500 mg once daily. Treatment course: 7-10 days.
- Pneumonia: 500 mg once or twice daily. Treatment course: 7-14 days.
- Urinary Tract Infections: 250-500 mg once daily. Treatment course: 7-10 days.
- Prostatitis: 500 mg once daily. Treatment course: 28 days.
- Skin and Soft Tissue Infections: 250-500 mg once or twice daily. Treatment course: 7-14 days.
In patients with impaired kidney function, the dosing regimen should be adjusted based on creatinine clearance levels.
Dosage and Administration:
Ilflox should be taken orally at a dose of 250-500 mg once or twice daily. The tablet should be swallowed whole with an adequate amount of fluid.
Contraindications:
- Hypersensitivity to levofloxacin or other quinolones;
- Epilepsy;
- Children and adolescents under 18 years of age;
- Pregnancy and lactation;
- History of tendon damage associated with quinolone use.
Special Precautions:
- Caution should be exercised when prescribing Ilflox in the following cases:
- Elderly patients (due to a higher likelihood of concurrent renal dysfunction).
Pregnancy and Lactation:
According to the FDA, this medication belongs to Category B. It is permissible to use the drug during pregnancy if the expected benefits outweigh the potential risks to the fetus.
